Browsing by Author Infante, Jeffrey

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 8 of 8
Issue DateTitleAuthor(s)Citation
2015Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase 1/2 clinical trialKefford, Richard (Rick); Long, Georgina; Menzies, Alexander Maxwel; Ashworth, Michelle T; et al, Various; Flaherty, Keith; Gonzalez, Rene; Hamid, Omid; Infante, Jeffrey; Kim, K B; Schuchter, Lynn; Swann, S; Weber, Jeffrey; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: MedicineCharacteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase 1/2 clinical trial, Annals of Oncology, vol.26, 2, 2015,pp 415-421
2014Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorKefford, Richard (Rick); Long, Georgina; Cebon, Jonathan Simon; et al, Various; Flaherty, Keith; Hamid, Omid; Infante, Jeffrey; Johnson, Douglas B; Kim, Kevin; McWilliams, Robert; Schuchter, Lynn; Sharfman, William; Weber, Jeffrey; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreCombined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor, Journal of Clinical Oncology, vol.32, 33, 2014,pp 3697-3704
2012Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialKefford, Richard (Rick); Long, Georgina; Arkenau, Tobias; Brown, Michael P.; et al, various; Falchook, GErald; Hamid, Omid; Infante, Jeffrey; Kim, Kevin; Kurzrock, Razelle; Millward, Michael; O'Day, Steven; Pavlick, Anna C.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreDabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial, The Lancet, vol.379, 9829, 2012,pp 1893-1901
2014Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF-inhibitor Dabrafenib (GSK2118436)Kefford, Richard (Rick); Long, Georgina; Arkenau, Hendrik-Tobias; Brown, Michael P.; Chin, Melvin; et al, .; Falchook, Gerald; Hamid, Omid; Infante, Jeffrey; Kim, Kevin; Kurzrock, Razelle; Millward, Michael; Pavlick, Anna C.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreDose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF-inhibitor Dabrafenib (GSK2118436), Clinical Cancer Research, vol.20, 17, 2014,pp 4449-4458
2016Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With TrametinibKefford, Richard (Rick); Long, Georgina; Cebon, Jonathan Simon; Daud, Adil; et al, .; Gonzalez, Rene; Hamid, Omid; Infante, Jeffrey; Kim, Kevin B; Schuchter, Lynn; Sosman, Jeffrey; Weber, Jeffrey; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: The Sydney Cancer CentreOverall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib, Journal of Clinical Oncology, vol.34, 8, 2016,pp 871-878
2016Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With TrametinibKefford, Richard (Rick); Long, Georgina; Cebon, Jonathan Simon; Daud, Adil; et al, .; Gonzalez, Rene; Hamid, Omid; Infante, Jeffrey; Kim, Kevin B; Schuchter, Lynn; Sosman, Jeffrey; Weber, Jeffrey; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: The Sydney Cancer CentreOverall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib, Journal of Clinical Oncology, vol.34, 8, 2016,pp 871-878
2013Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF InhibitorKefford, Richard (Rick); Long, Georgina; et al, Various; Fecher, Leslie A.; Gonzalez, Rene; Hwu, Patrick; Infante, Jeffrey; Kim, Kevin; McArthur, Grant A.; Millward, Michael; Pavlick, Anna C.; Ribas, Antoni; Sosman, Jeffrey; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentrePhase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor, Journal of Clinical Oncology, vol.31, 4, 2013,pp 482-489
2013Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)Kefford, Richard (Rick); Long, Georgina; Arkenau, Hendrik-Tobias; D'Andrea, Kurt; et al, Various; Falchook, Gerald; Greshock, Joel; Infante, Jeffrey; Letrero, Richard; Martin, Anne-Marie; Millward, Michael; Nathanson, Katherine L.; O'Day, Steven; Wubbenhorst, Bradley; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreTumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436), Clinical Cancer Research, vol.19, 17, 2013,pp 4868-4878